Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 248

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Pharmacokinetics, pharmacodynamics and safety of QGE 031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects

Open access
Arm, J. P., Bottoli, I., Skerjanec, A., Floch, D., Groenewegen, A., Maahs, S., Owen, C. E., Jones, I., Lowe, P. J.·2014·Clinical & Experimental Allergy

Abstract

Summary: Background: Using a monoclonal antibody with greater affinity for IgE than omalizumab, we examined whether more complete suppression of IgE provided greater pharmacodynamic effects, including suppression of skin prick responses to allergen. Objective: To explore the pharmacokinetics, pharmacodynamics and safety of QGE 031 (ligelizumab), a novel high‐affinity humanized monoclonal IgG1κ anti‐IgE. Methods: Preclinical assessments and two randomized, placebo‐controlled, double‐blind clinical trials were conducted in atopic subjects. The first trial administered single doses of QGE 031 (0.1–10 mg/kg) or placebo intravenously, while the second trial administered two to four doses of QGE 031 (0.2– 4 mg/kg) or placebo subcutaneously at 2‐week intervals. Both trials included an open‐label omalizumab arm. Results: Sixty of 73 (82%) and 96 of 110 (87%) subjects completed the intravenous and subcutaneous studies, respectively. Exposure to QGE 031 and its half‐life depended on the QGE 031 dose and serum IgE level. QGE 031 had a biexponential pharmacokinetic profile after intravenous administration and a terminal half‐life of approximately 20 days. QGE 031 demonstrated dose‐ and time‐dependent suppression of free IgE, basophil Fcε RI and basophil surface IgE superior in extent (free IgE and surface IgE) and duration to omalizumab. At Day 85, 6 weeks after the last dose, skin prick wheal responses to allergen were suppressed by > 95% and 41% in subjects treated subcutaneously with QGE 031 (2 mg/kg) or omalizumab, respectively (P < 0.001). Urticaria was observed in QGE 031‐ and placebo‐treated subjects and was accompanied by systemic symptoms in one subject treated with 10 mg/kg intravenous QGE 031. There were no serious adverse events. Conclusion and Clinical Relevance: These first clinical data for QGE 031, a high‐affinity IgG1κ anti‐IgE, demonstrate that increased suppression of free IgE compared with omalizumab translated to superior pharmacodynamic effects in atopic subjects, including those with high IgE levels. QGE 031 may therefore benefit patients unable to receive, or suboptimally treated with, omalizumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cea.12400

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 248

Metadata

Authors
Arm, J. P., Bottoli, I., Skerjanec, A., Floch, D., Groenewegen, A., Maahs, S., Owen, C. E., Jones, I., & Lowe, P. J.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2014-10-21
Volume
44
Issue
11
Pages
1371-1385
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W2102629488
Cited by
248
References
1
FWCI
16.02
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.